Mangrove Partners increased its holdings in Mylan N.V. (NASDAQ:MYL) by 14.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 806,902 shares of the company’s stock after purchasing an additional 100,000 shares during the quarter. Mylan makes up approximately 4.3% of Mangrove Partners’ holdings, making the stock its 10th largest holding. Mangrove Partners owned about 0.15% of Mylan worth $25,313,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Canada Pension Plan Investment Board boosted its position in Mylan by 99.5% during the 3rd quarter. Canada Pension Plan Investment Board now owns 1,217,413 shares of the company’s stock valued at $38,189,000 after acquiring an additional 607,094 shares in the last quarter. FMR LLC boosted its position in Mylan by 19.8% during the 2nd quarter. FMR LLC now owns 813,267 shares of the company’s stock valued at $31,572,000 after acquiring an additional 134,258 shares in the last quarter. Toronto Dominion Bank boosted its position in Mylan by 28.2% during the 3rd quarter. Toronto Dominion Bank now owns 200,017 shares of the company’s stock valued at $6,274,000 after acquiring an additional 43,943 shares in the last quarter. Swiss National Bank boosted its position in Mylan by 3.1% during the 2nd quarter. Swiss National Bank now owns 1,661,842 shares of the company’s stock valued at $64,513,000 after acquiring an additional 50,100 shares in the last quarter. Finally, Vivaldi Asset Management LLC bought a new stake in Mylan during the 2nd quarter valued at approximately $5,098,000. 73.86% of the stock is currently owned by institutional investors.
Several analysts have weighed in on MYL shares. Wells Fargo & Company set a $32.00 price objective on Mylan and gave the company a “hold” rating in a research report on Wednesday, October 4th. Morgan Stanley lifted their price objective on Mylan from $36.00 to $39.00 and gave the company an “equal weight” rating in a research report on Friday, October 6th. BidaskClub raised Mylan from a “hold” rating to a “buy” rating in a research report on Friday, October 27th. BMO Capital Markets reaffirmed a “buy” rating and set a $45.00 price objective on shares of Mylan in a research report on Friday, September 29th. Finally, ValuEngine raised Mylan from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and thirteen have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $41.49.
Mylan (NASDAQ:MYL) last released its earnings results on Monday, November 6th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.20 by ($0.10). Mylan had a net margin of 7.28% and a return on equity of 20.63%. The business had revenue of $2.99 billion for the quarter, compared to analysts’ expectations of $3.09 billion. During the same quarter in the previous year, the business posted $1.38 earnings per share. Mylan’s revenue for the quarter was down 2.3% on a year-over-year basis. sell-side analysts predict that Mylan N.V. will post 4.56 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Mangrove Partners Has $25.31 Million Position in Mylan N.V. (MYL)” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2017/12/11/mangrove-partners-has-25-31-million-position-in-mylan-n-v-myl.html.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.